Future Perspectives

This version of the course is no longer available.
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course Multi-drug Resistant Organisms: MRSA, VRE, and Clostridium difficile. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Multi-drug Resistant Organisms: MRSA, VRE, and Clostridium difficile (online CE course)
Future Perspectives

With MRSA becoming the "new normal" in many areas, clinicians will have to define the role of up to a dozen anti-MRSA drugs. Alternatives to vancomycin include older drugs like clindamycin, doxycycline, and trimethoprim/sulfamethoxazole, and newer agents like linezolid and daptomycin for serious infections. There are also a number of drugs under development including enhanced glycopeptides – dalbavancin, oritavancin, telavancin, and anti-MRSA cephalosporins.